![](/img/cover-not-exists.png)
Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
Haynes, Richard, Valdes-Marquez, Elsa, Hopewell, Jemma C., Chen, Fang, Li, Jing, Parish, Sarah, Landray, Martin J., Armitage, Jane, Haynes, Richard, Valdes-Marquez, Elsa, Hopewell, Jemma C., Chen, FanVolume:
41
Language:
english
Journal:
Clinical Therapeutics
DOI:
10.1016/j.clinthera.2019.06.012
Date:
September, 2019
File:
PDF, 297 KB
english, 2019